• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Helix BioMedix Inc

  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Disease Focus
    • DNA Damage Response (DDR)
    • Xeroderma Pigmentosum
  • Programs
    • Pharma
    • Personal Care
  • News
    • Press Releases
    • Presentations
    • Scientific Publications
  • Investors
    • Stock Information
    • IR Updates
    • Proxy
    • Corporate Governance
  • Contact Page
You are here: Home / Investors

Investors

Data projected on a screen

Helix BioMedix, Inc., is committed to building long term shareholder value through development of novel drugs for rare dermatological conditions with unmet needs and strategic management of our diverse peptide library.

TRANSFER AGENT

Broadridge Financial Solutions, Inc.

Website: www.shareholder.broadridge.com
E-mail: shareholder@broadridge.com
Telephone: 1-877-830-4936 or 720-378-5591

Mail: Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717

INVESTOR RELATIONS CONTACT
E-mail: ir@helixbiomedix.com

Primary Sidebar

Footer

COMPANY PROFILE

Helix BioMedix is a biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum.  Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body’s innate immunity.

 

 

 

 

Terms & Conditions | Privacy Policy

Search

 

©2023 HELIX BIOMEDIX, INC.
ALL RIGHTS RESERVED

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Copyright © 2025 · Executive Pro On Genesis Framework · WordPress · Log in